Vaccines

A technique for analyzing specific T-cell responses could pave the way for more rationally designed vaccines

A*STAR’s new vaccine, based on a virus-like particle technology created by Cytos Biotechnology AG, could strengthen Singapore’s ability to tackle influenza pandemics

Exploiting the early immune response in Chikungunya fever promises to provide protection

A vaccine against a devastating form of malaria common in Asia and South America is one step closer thanks to a long-awaited methodological advance

Genomic technologies developed by A*STAR’s Singapore Immunology Network (SIgN) form the basis for a new vaccine development platform that could pave the way for cost-effective personalized therapy